Paper26536626
Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Toy M and 2 others. PLoS One, 2015. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. Papers, record 26536626. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26536626
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cost-Benefit Analysis | Major topic |
| Hepatitis B, Chronic | Major topic |
| National Health Programs | Major topic |
| Antiviral Agents | |
| China | |
| Drugs, Generic | |
| Guanine | |
| Hepatitis B e Antigens | |
| Humans | |
| Markov Chains | |
| Quality-Adjusted Life Years | |
| Tenofovir |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16729316 | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Hepatology | 2006 | https://conductscience.org/library/papers/16729316 | PubMed |
| 2 | 21036792 | Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. | Gut | 2011 | https://conductscience.org/library/papers/21036792 | PubMed |
| 3 | 18179664 | The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. | Value Health | 2008 | https://conductscience.org/library/papers/18179664 | PubMed |
| 4 | 17133475 | Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. | Hepatology | 2006 | https://conductscience.org/library/papers/17133475 | PubMed |
| 5 | 19303414 | Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. | Gastroenterology | 2009 | https://conductscience.org/library/papers/19303414 | PubMed |
| 6 | 19918971 | Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. | Hepatology | 2010 | https://conductscience.org/library/papers/19918971 | PubMed |
| 7 | 19669285 | Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. | Hepatol Int | 2008 | https://conductscience.org/library/papers/19669285 | PubMed |
| 8 | 19729084 | Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. | Vaccine | 2009 | https://conductscience.org/library/papers/19729084 | PubMed |
| 9 | 19054588 | EASL Clinical Practice Guidelines: management of chronic hepatitis B. | J Hepatol | 2009 | https://conductscience.org/library/papers/19054588 | PubMed |
| 10 | 24615378 | Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. | Gut | 2014 | https://conductscience.org/library/papers/24615378 | PubMed |
| 11 | 19669245 | HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. | Hepatol Int | 2009 | https://conductscience.org/library/papers/19669245 | PubMed |
| 12 | 15602167 | Cost of chronic hepatitis B infection in China. | J Clin Gastroenterol | 2004 | https://conductscience.org/library/papers/15602167 | PubMed |
| 13 | 19455130 | Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. | Am J Gastroenterol | 2009 | https://conductscience.org/library/papers/19455130 | PubMed |
| 14 | 20483498 | Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. | J Hepatol | 2010 | https://conductscience.org/library/papers/20483498 | PubMed |
| 15 | 17192114 | Rates and probabilities in economic modelling: transformation, translation and appropriate application. | Pharmacoeconomics | 2007 | https://conductscience.org/library/papers/17192114 | PubMed |
| 16 | 17310821 | Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. | Antivir Ther | 2006 | https://conductscience.org/library/papers/17310821 | PubMed |
| 17 | 23364953 | Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. | Hepatology | 2013 | https://conductscience.org/library/papers/23364953 | PubMed |
| 18 | 12823597 | Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. | J Viral Hepat | 2003 | https://conductscience.org/library/papers/12823597 | PubMed |
| 19 | 17499584 | Hepatitis B in China. | Lancet | 2007 | https://conductscience.org/library/papers/17499584 | PubMed |
| 20 | 16461777 | Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. | Gut | 2006 | https://conductscience.org/library/papers/16461777 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35801242 | Cost-Benefit Analysis of Vaccination Strategies to Prevent Mother-to-Child Transmission of the Hepatitis B Virus Using a Markov Model Decision Tree. | Front Public Health | 2022 | https://conductscience.org/library/papers/35801242 | PubMed |
| 35796158 | Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. | J Glob Health | 2022 | https://conductscience.org/library/papers/35796158 | PubMed |
| 34427860 | APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. | Hepatol Int | 2021 | https://conductscience.org/library/papers/34427860 | PubMed |
| 33248510 | Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. | Value Health | 2020 | https://conductscience.org/library/papers/33248510 | PubMed |
| 33197397 | Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33197397 | PubMed |
| 32854458 | Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. | Clin Mol Hepatol | 2020 | https://conductscience.org/library/papers/32854458 | PubMed |
| 31574103 | Development and application of a framework to estimate health care costs in China: The cervical cancer example. | PLoS One | 2019 | https://conductscience.org/library/papers/31574103 | PubMed |
| 31428938 | Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. | Pharmacoecon Open | 2020 | https://conductscience.org/library/papers/31428938 | PubMed |
| 30931346 | Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. | Open Forum Infect Dis | 2019 | https://conductscience.org/library/papers/30931346 | PubMed |
| 29633520 | How far are we from viral hepatitis elimination service coverage targets? | J Int AIDS Soc | 2018 | https://conductscience.org/library/papers/29633520 | PubMed |
| 29447614 | Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. | Glob Health Action | 2018 | https://conductscience.org/library/papers/29447614 | PubMed |
| 28963103 | The role of routine screening in blood-borne pathogens in Chinese patients undergoing joint arthroplasty. | Bone Joint Res | 2017 | https://conductscience.org/library/papers/28963103 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26536626
GET https://conductscience.org/api/papers/v1/26536626/references?page=2